Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. Co. is developing treatments for parties with cancers in need of new treatment options. Its product portfolio includes seclidemstat, an oral novel small molecule inhibitor of the LSD1 enzyme and the Co.'s lead candidate, which is being studied as a potential treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options, and SP-3164, an oral small molecule protein degrader being developed for the treatment of Non-Hodgkins Lymphoma. SP-3164 is a small molecule protein degrader, and seclidemstat (SP-2577) is a small molecule inhibitor. We show 24 historical shares outstanding datapoints in our SLRX shares outstanding history coverage, used to compute SLRX market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing SLRX market cap history over the course of time is important for investors
interested in comparing SLRX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of SLRX versus a peer is one thing; comparing
SLRX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like SLRX can fluctuate over the course of history.
With this page we aim to empower investors researching SLRX by allowing them to research the SLRX market cap history. |
Free SLRX Email Alerts:
Video: The Importance of Market Cap
